As a reminder, for Total Edwards, we expect sales of $5,000,000,000 to $6,000,000,000 for TAVR, dollars 3,700,000,000 to $4,000,000,000 for TMTT, dollars 140,000,000 to $170,000,000 For Surgical Structural Heart, dollars 8.70,000,000 to $950,000,000 and for Critical Care, dollars 820,000,000 to $900,000,000 We are also maintaining our full year adjusted earnings per share guidance of $2.50 to $2.65 representing mid teens growth over 2021. And now I'll cover additional details of our results. For the Q1, our adjusted gross profit margin was 77.8% compared to 76.0% in the same period last year. As we expected, this improvement was driven by the positive impact from foreign exchange, primarily the Strengthening of the dollar against the euro and the yen. We continue to expect our full year 2022 adjusted gross profit Margin to be between 78% and 79%.